StarMine

StarMine Therapeutics is a precision medicine biotechnology company dedicated to developing next-generation therapies for cancer. Founded by leading scientists from the Broad Institute and Dana-Farber Cancer Institute, the company leverages advanced genomic and proteomic insights to target previously undruggable drivers of malignancy. Their approach focuses on identifying specific molecular vulnerabilities in defined patient populations to improve treatment outcomes. StarMine is currently in the pre-clinical stage, building a robust pipeline of small molecule candidates, specifically focusing on molecular glues. The company is backed by Deerfield Management and is headquartered in the biotechnology hub of Cambridge, Massachusetts.